Pfizer’s Talapro-3 phase 3 trial cut the risk of radiographic progression or death by 52% in men with HRR gene-mutated metastatic castration-sensitive prostate cancer, and it did so across the full mutation spectrum, not just BRCA2.
Presented at the 2026 ASCO annual meeting in Chicago and simultaneously published in The New England Journal of Medicine, the trial exceeded its pre-specified hazard ratio target of 0.63. At three years, 77% of patients in the Talzenna arm were free from confirmed progression versus 56% in the control arm. The non-BRCA subgroup showed a 43% rPFS improvement; the CDK12 subgroup hit 72%.
That breadth is the commercial story. J&J’s Akeega, a fixed combination of niraparib and abiraterone, earned an FDA label restricted to BRCA2 mutation patients after an exploratory analysis showed non-BRCA patients gained only a 12% rPFS improvement versus 54% for BRCA2-mutated disease. Pfizer’s non-BRCA result at 43% doesn’t have that problem.
I read the Amplitude data when Akeega’s mCSPC label came out in December 2025, and the FDA’s BRCA2 restriction looked inevitable once the subgroup numbers were in. At 43% rPFS improvement in non-BRCA patients, it’s a different dataset — cross-subgroup consistency from CDK12 to ATM that makes a broad label defensible. If Pfizer pursues an mCSPC indication, the non-BRCA data are what carries it.
About 30% of mCSPC patients harbor HRR gene alterations, in a population of roughly 330,000 new U.S. prostate cancer diagnoses expected in 2026. Overall survival data are immature but favor the combo by 23%. Anemia of grade 3 or higher hit 51% of combo patients versus 3% in control.
Worth auditing your biomarker testing panels before the FDA label review lands.
Rebecca Lauren